Kezar Life Sciences (KZR) Equity Ratio (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Equity Ratio for 5 consecutive years, with 0.91 as the latest value for Q4 2025.
- Quarterly Equity Ratio rose 13.13% to 0.91 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.91 through Dec 2025, up 13.13% year-over-year, with the annual reading at 0.91 for FY2025, 13.13% up from the prior year.
- Equity Ratio hit 0.91 in Q4 2025 for Kezar Life Sciences, up from 0.85 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.94 in Q2 2022 to a low of 0.81 in Q4 2024.
- Historically, Equity Ratio has averaged 0.88 across 5 years, with a median of 0.89 in 2023.
- Biggest five-year swings in Equity Ratio: decreased 6.77% in 2023 and later increased 13.13% in 2025.
- Year by year, Equity Ratio stood at 0.9 in 2021, then fell by 0.28% to 0.9 in 2022, then decreased by 5.89% to 0.85 in 2023, then decreased by 4.69% to 0.81 in 2024, then increased by 13.13% to 0.91 in 2025.
- Business Quant data shows Equity Ratio for KZR at 0.91 in Q4 2025, 0.85 in Q3 2025, and 0.84 in Q2 2025.